Emerging roles of ferroptosis in liver pathophysiology
Ferroptosis is a widely recognized process of regulated cell death linking redox state, metabolism, and human health. It is considered a defense mechanism against extensive lipid peroxidation, a complex process that may disrupt the membrane integrity, eventually leading to toxic cellular injury. Ferroptosis is controlled by iron, reactive oxygen species, and polyunsaturated fatty acids. Accumulating evidence has addressed that ferroptosis plays an unneglectable role in regulating the development and progression of multiple pathologies of the liver, including hepatocellular carcinoma, liver fibrosis, nonalcoholic steatosis, hepatic ischemia-reperfusion injury, and liver failure. This review may increase our understating of the cellular and molecular mechanisms of liver disease progression and establish the foundation of strategies for pharmacological intervention.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:43 |
|---|---|
| Enthalten in: |
Archives of pharmacal research - 43(2020), 10 vom: 20. Okt., Seite 985-996 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kim, Kyu Min [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 26.07.2021 Date Revised 26.07.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s12272-020-01273-8 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM316485942 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM316485942 | ||
| 003 | DE-627 | ||
| 005 | 20231225161202.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s12272-020-01273-8 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1054.xml |
| 035 | |a (DE-627)NLM316485942 | ||
| 035 | |a (NLM)33079307 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kim, Kyu Min |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Emerging roles of ferroptosis in liver pathophysiology |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.07.2021 | ||
| 500 | |a Date Revised 26.07.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Ferroptosis is a widely recognized process of regulated cell death linking redox state, metabolism, and human health. It is considered a defense mechanism against extensive lipid peroxidation, a complex process that may disrupt the membrane integrity, eventually leading to toxic cellular injury. Ferroptosis is controlled by iron, reactive oxygen species, and polyunsaturated fatty acids. Accumulating evidence has addressed that ferroptosis plays an unneglectable role in regulating the development and progression of multiple pathologies of the liver, including hepatocellular carcinoma, liver fibrosis, nonalcoholic steatosis, hepatic ischemia-reperfusion injury, and liver failure. This review may increase our understating of the cellular and molecular mechanisms of liver disease progression and establish the foundation of strategies for pharmacological intervention | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Cell death | |
| 650 | 4 | |a Ferroptosis | |
| 650 | 4 | |a Iron | |
| 650 | 4 | |a Liver | |
| 650 | 4 | |a ROS | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Caffeic Acids |2 NLM | |
| 650 | 7 | |a Cyclohexylamines |2 NLM | |
| 650 | 7 | |a Fatty Acids, Unsaturated |2 NLM | |
| 650 | 7 | |a Hydroxymethylglutaryl-CoA Reductase Inhibitors |2 NLM | |
| 650 | 7 | |a Phenylenediamines |2 NLM | |
| 650 | 7 | |a Quinoxalines |2 NLM | |
| 650 | 7 | |a Reactive Oxygen Species |2 NLM | |
| 650 | 7 | |a Spiro Compounds |2 NLM | |
| 650 | 7 | |a cinnamyl-3,4-dihydroxycyanocinnamate |2 NLM | |
| 650 | 7 | |a ferrostatin-1 |2 NLM | |
| 650 | 7 | |a liproxstatin-1 |2 NLM | |
| 650 | 7 | |a Cycloheximide |2 NLM | |
| 650 | 7 | |a 98600C0908 |2 NLM | |
| 650 | 7 | |a Iron |2 NLM | |
| 650 | 7 | |a E1UOL152H7 |2 NLM | |
| 650 | 7 | |a Deferoxamine |2 NLM | |
| 650 | 7 | |a J06Y7MXW4D |2 NLM | |
| 700 | 1 | |a Cho, Sam Seok |e verfasserin |4 aut | |
| 700 | 1 | |a Ki, Sung Hwan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Archives of pharmacal research |d 1991 |g 43(2020), 10 vom: 20. Okt., Seite 985-996 |w (DE-627)NLM079753698 |x 1976-3786 |7 nnns |
| 773 | 1 | 8 | |g volume:43 |g year:2020 |g number:10 |g day:20 |g month:10 |g pages:985-996 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s12272-020-01273-8 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 43 |j 2020 |e 10 |b 20 |c 10 |h 985-996 | ||